433 related articles for article (PubMed ID: 18503001)
1. Pharmacokinetics of intraocular drug delivery of Oregon green 488-labeled triamcinolone by subtenon injection using ocular fluorophotometry in rabbit eyes.
Lee SJ; Kim ES; Geroski DH; McCarey BE; Edelhauser HF
Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4506-14. PubMed ID: 18503001
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry.
Ghate D; Brooks W; McCarey BE; Edelhauser HF
Invest Ophthalmol Vis Sci; 2007 May; 48(5):2230-7. PubMed ID: 17460284
[TBL] [Abstract][Full Text] [Related]
3. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide.
Robinson MR; Lee SS; Kim H; Kim S; Lutz RJ; Galban C; Bungay PM; Yuan P; Wang NS; Kim J; Csaky KG
Exp Eye Res; 2006 Mar; 82(3):479-87. PubMed ID: 16168412
[TBL] [Abstract][Full Text] [Related]
4. Effect of intraocular pressure (IOP) and choroidal circulation on controlled episcleral drug delivery to retina/vitreous.
Li J; Lan B; Li X; Sun S; Lu P; Cheng L
J Control Release; 2016 Dec; 243():78-85. PubMed ID: 27717742
[TBL] [Abstract][Full Text] [Related]
5. Trans-scleral permeability of Oregon green 488.
Lee SJ; Kim SJ; Kim ES; Geroski DH; McCarey BE; Edelhauser HF
J Ocul Pharmacol Ther; 2008 Dec; 24(6):579-86. PubMed ID: 19049298
[TBL] [Abstract][Full Text] [Related]
6. In vivo ocular fluorophotometry: delivery of fluoresceinated dextrans via transscleral diffusion in rabbits.
Berezovsky DE; Patel SR; McCarey BE; Edelhauser HF
Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7038-45. PubMed ID: 21791594
[TBL] [Abstract][Full Text] [Related]
7. Delivery from episcleral exoplants.
Pontes de Carvalho RA; Krausse ML; Murphree AL; Schmitt EE; Campochiaro PA; Maumenee IH
Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4532-9. PubMed ID: 17003449
[TBL] [Abstract][Full Text] [Related]
8. Ocular tissue distribution of betamethasone after anterior-episcleral, posterior-episcleral, and anterior-intrascleral placement of nonbiodegradable implants.
Okabe K; Kimura H; Okabe J; Ogura Y
Retina; 2007; 27(6):770-7. PubMed ID: 17621189
[TBL] [Abstract][Full Text] [Related]
9. Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model.
Chen M; Li X; Liu J; Han Y; Cheng L
J Control Release; 2015 Apr; 203():109-17. PubMed ID: 25700623
[TBL] [Abstract][Full Text] [Related]
10. Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection.
Inoue M; Takeda K; Morita K; Yamada M; Tanigawara Y; Oguchi Y
Am J Ophthalmol; 2004 Dec; 138(6):1046-8. PubMed ID: 15629301
[TBL] [Abstract][Full Text] [Related]
11. Transscleral Coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels.
Behar-Cohen FF; El Aouni A; Gautier S; David G; Davis J; Chapon P; Parel JM
Exp Eye Res; 2002 Jan; 74(1):51-9. PubMed ID: 11878818
[TBL] [Abstract][Full Text] [Related]
12. Intraocular concentration of triamcinolone acetonide after intravitreal injection in the rabbit eye.
Kamppeter BA; Cej A; Jonas JB
Ophthalmology; 2008 Aug; 115(8):1372-5. PubMed ID: 18355920
[TBL] [Abstract][Full Text] [Related]
13. Trans-scleral diffusion of triamcinolone acetonide.
Mora P; Eperon S; Felt-Baeyens O; Gurny R; Sagodira S; Breton P; Guex-Crosier Y
Curr Eye Res; 2005 May; 30(5):355-61. PubMed ID: 16020266
[TBL] [Abstract][Full Text] [Related]
14. Effect of benzalkonium chloride on transscleral drug delivery.
Okabe K; Kimura H; Okabe J; Kato A; Shimizu H; Ueda T; Shimada S; Ogura Y
Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):703-8. PubMed ID: 15671302
[TBL] [Abstract][Full Text] [Related]
15. Transcleral delivery of triamcinolone acetonide and ranibizumab to retinal tissues using macroesis.
Singh RP; Mathews ME; Kaufman M; Riga A
Br J Ophthalmol; 2010 Feb; 94(2):170-3. PubMed ID: 20139290
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal pharmacokinetics after posterior subtenon triamcinolone acetonide injection in vitrectomized rabbit eyes.
Park HJ; Lee JE; Kim SI; Pak KY; Oum BS; Lee JS; Jung JH; Lee JE
Retina; 2014 Apr; 34(4):801-6. PubMed ID: 24077088
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal triamcinolone acetonide concentration after subtenon injection.
Thomas ER; Wang J; Ege E; Madsen R; Hainsworth DP
Am J Ophthalmol; 2006 Nov; 142(5):860-1. PubMed ID: 17056371
[TBL] [Abstract][Full Text] [Related]
18. Episcleral drug film for better-targeted ocular drug delivery and controlled release using multilayered poly-ε-caprolactone (PCL).
Sun S; Li J; Li X; Lan B; Zhou S; Meng Y; Cheng L
Acta Biomater; 2016 Jun; 37():143-54. PubMed ID: 27071973
[TBL] [Abstract][Full Text] [Related]
19. Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling.
Ranta VP; Urtti A
Adv Drug Deliv Rev; 2006 Nov; 58(11):1164-81. PubMed ID: 17069929
[TBL] [Abstract][Full Text] [Related]
20. Development of biodegradable controlled release scleral systems of triamcinolone acetonide.
Blatsios G; Tzimas AS; Mattheolabakis G; Panagi Z; Avgoustakis K; Gartaganis SP
Curr Eye Res; 2010 Oct; 35(10):916-24. PubMed ID: 20858113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
